Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy
Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
Sun Pharma said had a teleconference call with the US Food and Drug Administration (USFDA) regarding a pulmonary embolism (serious adverse events) occurring at the 12 mg dose
Several late-stage pipeline products have the potential to address some of these unmet needs
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
The disease is caused by a mutation in the gene encoding HMG CoA reductase, inhibiting the enzyme’s activity.
MoES have identified a potent Anti-cancer molecule named GS/IICT5/6
Subscribe To Our Newsletter & Stay Updated
